Cargando…
How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
IN BRIEF As more patents on biological medicines expire, increased numbers of biologic copies, referred to as “biosimilars,” will likely become available in the United States in the coming years. With greater availability and the drive for health care savings, the use of biosimilars and of “follow-o...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669137/ https://www.ncbi.nlm.nih.gov/pubmed/29109610 http://dx.doi.org/10.2337/cd16-0072 |